Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging ...

Eli Lilly ( LLY +0.87%) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

The City of Providence, along other municipalities and states, is taking big pharma to court over the price of insulin.

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...

A new University of Warwick study evaluating W8Buddy, a digital specialist weight management service, has started patient recruitment, offering a solution to improve access to obesity care across heal ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...